CDK

CDK Extends Relationship With Group 1 Automotive

Retrieved on: 
Dienstag, Mai 28, 2024
Technology, Automotive, General Automotive, Vehicle Technology, Automotive Manufacturing, Specialty, Manufacturing, Software, Retail, API, CRM, Digital, CDK, Original equipment manufacturer, Group 1, GPI, Group 1 Automotive, Car dealership

As a close partner and early adopter of CDK, the extension allows Group 1 to further leverage the capabilities of the CDK Modern Retail Suite, which includes Digital Retailing, CRM, and F&I.

Key Points: 
  • As a close partner and early adopter of CDK, the extension allows Group 1 to further leverage the capabilities of the CDK Modern Retail Suite, which includes Digital Retailing, CRM, and F&I.
  • Group 1 can also build, innovate and integrate apps and real-time workflows with APIs delivered through Fortellis —the automotive industry’s leading developer platform.
  • “Extending our relationship with CDK brings us what we believe are the best scalable solutions available.”
    As of 2024, CDK software is relied upon to power the operations of the majority of franchise dealerships in North America, including five of the six publicly held dealership groups in the U.S.
    “We are excited to extend our longstanding relationship with Group 1 as we continue to drive digital transformation across the automotive industry with the depth and breadth of CDK software,” said Brian MacDonald, president and chief executive officer, CDK.
  • “CDK is uniquely positioned at the center of the automotive ecosystem, and this relationship is a testament to the hard work our team has done for decades to help better connect dealers, OEMs and consumers together.”
    For more information about the CDK Dealership Xperience, visit cdk.com .

Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress

Retrieved on: 
Donnerstag, Mai 23, 2024
Team Impulse, ARVN, CDK4, HER2, Chimera, Congress, Prostate cancer, CDK, Abstract, Society, Proteolysis, PROTAC, Birth control

NEW HAVEN, Conn., May 23, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two abstracts, including one for ARV-766 in prostate cancer and one for TACTIVE-K, a Phase 1b/2 clinical trial with vepdegestrant, a novel investigational oral PROteolysis Targeting Chimera (PROTAC®) ER degrader, in combination with Pfizer’s atirmociclib (PF-07220060), an investigational CDK4 inhibitor, were accepted for presentation at the 2024 American Society of Clinical Oncology Annual Congress held May 31 to June 4, 2024, in Chicago, IL.

Key Points: 
  • NEW HAVEN, Conn., May 23, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two abstracts, including one for ARV-766 in prostate cancer and one for TACTIVE-K, a Phase 1b/2 clinical trial with vepdegestrant, a novel investigational oral PROteolysis Targeting Chimera (PROTAC®) ER degrader, in combination with Pfizer’s atirmociclib (PF-07220060), an investigational CDK4 inhibitor, were accepted for presentation at the 2024 American Society of Clinical Oncology Annual Congress held May 31 to June 4, 2024, in Chicago, IL.
  • Presentation details are as follows:
    Title: ARV-766, a PROteolysis TArgeting Chimera (PROTAC) androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC): initial results of a phase 1/2 study
    Presentation Type and Abstract Number: Rapid Oral Abstract, 5011
    Title: TACTIVE-K: phase 1b/2 study of vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, in combination with PF-07220060, a cyclin-dependent kinase (CDK)4 inhibitor, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer
    Presentation Type and Abstract Number: Trial-in-Progress (TiP) TPS1131, Poster 103b

Traws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Donnerstag, Mai 16, 2024
ARK, Insurance, Patient, LP, Risk, Urinary tract infection, Neutropenia, COVID19, Sale, Ritonavir, CDK, Cancer, Acquisition, OrbiMed, Omicron, COVID, COVID 19, Research, G&A, Infection, Delta, SARS-CoV-2, Pharmaceutical industry

NEWTOWN, Pa., May 16, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (“Traws” or “Traws Pharma”), a clinical stage biopharmaceutical company developing oral small molecules for respiratory viral diseases and cancer, today announced financial results for the first quarter of 2024, and provided a business update.

Key Points: 
  • Excellent pipeline progress, led by candidates for COVID 19, influenza, and oncology programs
    NEWTOWN, Pa., May 16, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (“Traws” or “Traws Pharma”), a clinical stage biopharmaceutical company developing oral small molecules for respiratory viral diseases and cancer, today announced financial results for the first quarter of 2024, and provided a business update.
  • “2024 has already been a transformative year for Traws Pharma to advance our portfolio of novel treatments for serious respiratory infections and oncology programs.
  • Furthermore, we completed the last dose escalation cohort for our CDK4+ inhibitor, narazaciclib,” stated Werner Cautreels, Ph.D., Chief Executive Officer of Traws Pharma.
  • The Company believes that its cash and cash equivalents will be sufficient to fund ongoing clinical trials and business operations into the fourth quarter of 2024.

Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024

Retrieved on: 
Mittwoch, Mai 15, 2024
ASX, Patient, CD4, Plasma, MBC, Pharmacodynamics, Safety, Autoimmune disease, RECIST, IMM, Poster, Congress, Blood, CDK, Cancer, Eftilagimod alpha, MHC, Paclitaxel, ESMO, Oncology, CD8, TNBC, Gamma ray, MHC class II, Pharmaceutical industry

SYDNEY, AUSTRALIA, May 15, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces encouraging efficacy, safety, and pharmacodynamic data from the safety lead-in of the AIPAC-003 Phase II/III trial presented at the European Society for Medical Oncology (ESMO) Breast Cancer 2024 Congress. This lead-in represents the first ever 90mg dosing of eftilagimod alpha (“efti”), a soluble LAG-3 protein and MHC Class II agonist, given in combination with weekly paclitaxel.

Key Points: 
  • During the immuno-oncology (IO)-chemotherapy treatment of efti and paclitaxel, this patient achieved a partial response (PR) that subsequently turned into a CR.
  • As of the data cut-off (April 3), no dose-limiting toxicities and no treatment-emergent adverse events of grade 3 or higher severity were recorded.
  • Further data updates in terms of safety and efficacy from AIPAC-003 are expected in CY2024.
  • The ESMO Breast 2024 poster will be available on the Posters & Publications section of Immutep’s website.

Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update

Retrieved on: 
Dienstag, Mai 14, 2024
Patient, Clinical trial, Safety, Lymphoma, CYCC, CDK, Research, POC, ASCO, Cyclacel, Society, T-cell lymphoma, Webcast, Annual general meeting

BERKELEY HEIGHTS, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today first quarter financial results and provided a business update.

Key Points: 
  • BERKELEY HEIGHTS, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today first quarter financial results and provided a business update.
  • “Receipt of $8.0 million gross proceeds in a private placement together with existing resources support our ongoing clinical program.
  • The Company estimates that its current cash resources will fund planned programs into the fourth quarter of 2024.
  • Webcast link
    For the live and archived webcast, please visit the Corporate Presentations page on the Cyclacel website at www.cyclacel.com .

Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress

Retrieved on: 
Donnerstag, Mai 9, 2024
Congress, CDK, Proteolysis, HER2, Breast cancer, Oncology, ARVN, ESMO, Chimera, Patient, Team Impulse, Poster, Clinical trial, PROTAC

NEW HAVEN, Conn., May 09, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two posters, including updated clinical trial data, for vepdegestrant will be presented at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress held from May 15-17, 2024, in Berlin, Germany.

Key Points: 
  • NEW HAVEN, Conn., May 09, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two posters, including updated clinical trial data, for vepdegestrant will be presented at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress held from May 15-17, 2024, in Berlin, Germany.
  • Vepdegestrant is a novel investigational PROTAC® estrogen receptor (ER) degrader that is being jointly developed by Arvinas and Pfizer for the treatment of patients with early and locally advanced or metastatic ER positive/human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) breast cancer.
  • Poster session details are as follows:
    Time: 12:00 – 1:00 p.m. CET/ 6:00 – 7:00 a.m.
  • ET
    Poster Title and Number: Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, plus palbociclib (palbo) in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: updated phase 1b cohort results, Poster 218P
    Presentation Type and Abstract Number: Abstract, 453
    Poster Title and Number: TACTIVE-K: phase 1b/2 study of vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, in combination with PF-07220060, a cyclin-dependent kinase (CDK)4 inhibitor, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer, Poster 264
    Presentation Type and Abstract Number: Trial-in-Progress (TiP), 488

As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up Response

Retrieved on: 
Dienstag, April 30, 2024
FDA, Pancreatic cancer, News, Breast, Fulvestrant, Fast track (FDA), ONC, MBC, PFE, Classification, ICE3, Breast cancer, Paclitaxel, Learning, Kidney, Woman, Economics, Hand, Traction, TSX, Optimism, Eli Lilly and Company, Patient satisfaction, Proteolysis, Freezing, Survival, NEO, Marketing, Clinical trial, CDK, University, Progression-free survival, Recurrence, Disease, Chimera, Patient, Liver, Neoplasm, Type, Growth, Pharmaceutical industry

VANCOUVER, BC, April 30, 2024 /PRNewswire/ -- USA News Group – An alarming rise in early-onset cancers has medical experts very concerned, as cancer cases in younger people are rising sharply. In particular, a surge in cases of breast cancer is being witnessed in Canada, the USA, and the EU, with extra concern to patients thought to be in remission contracting breast cancer a second time, according to a new study from the University of Cambridge. However, there's still optimism towards new treatments, and significant growth of 9.3% CAGR in the metastatic HR+/HER2- breast cancer market through 2032 has treatment developers working harder to make gains for patients. Among the biotech companies currently making strides are Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), IceCure Medical Ltd (NASDAQ: ICCM), Atossa Therapeutics, Inc. (NASDAQ: ATOS), Arvinas, Inc. (NASDAQ: ARVN), and Pfizer Inc. (NYSE: PFE) (NEO: PFE).

Key Points: 
  • Recently, Oncolytics announced that they had submitted a Type C meeting request to the FDA to discuss a forthcoming trial for pelareorep aimed at treating HR+/HER2- metastatic breast cancer (mBC) patients.
  • "A key focus for Oncolytics in 2024 is defining the regulatory path for pelareorep in breast cancer treatment," said Matt Coffey, President and CEO of Oncolytics.
  • "We are optimistic that pelareorep, in combination with paclitaxel, could significantly enhance clinical outcomes for patients with HR+/HER2- metastatic breast cancer.
  • The company looks forward to meeting with the FDA in Q2 2024 to finalize the trial design and goals for using pelareorep in treating metastatic breast cancer.

As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up Response

Retrieved on: 
Dienstag, April 30, 2024
FDA, Pancreatic cancer, News, Breast, Fulvestrant, Fast track (FDA), ONC, MBC, PFE, Classification, ICE3, Breast cancer, Paclitaxel, Learning, Kidney, Woman, Economics, Hand, Traction, TSX, Optimism, Eli Lilly and Company, Patient satisfaction, Proteolysis, Freezing, Survival, NEO, Marketing, Clinical trial, CDK, University, Progression-free survival, Recurrence, Disease, Chimera, Patient, Liver, Neoplasm, Type, Growth, Pharmaceutical industry

VANCOUVER, BC, April 30, 2024 /PRNewswire/ -- USA News Group – An alarming rise in early-onset cancers has medical experts very concerned, as cancer cases in younger people are rising sharply. In particular, a surge in cases of breast cancer is being witnessed in Canada, the USA, and the EU, with extra concern to patients thought to be in remission contracting breast cancer a second time, according to a new study from the University of Cambridge. However, there's still optimism towards new treatments, and significant growth of 9.3% CAGR in the metastatic HR+/HER2- breast cancer market through 2032 has treatment developers working harder to make gains for patients. Among the biotech companies currently making strides are Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), IceCure Medical Ltd (NASDAQ: ICCM), Atossa Therapeutics, Inc. (NASDAQ: ATOS), Arvinas, Inc. (NASDAQ: ARVN), and Pfizer Inc. (NYSE: PFE) (NEO: PFE).

Key Points: 
  • Recently, Oncolytics announced that they had submitted a Type C meeting request to the FDA to discuss a forthcoming trial for pelareorep aimed at treating HR+/HER2- metastatic breast cancer (mBC) patients.
  • "A key focus for Oncolytics in 2024 is defining the regulatory path for pelareorep in breast cancer treatment," said Matt Coffey, President and CEO of Oncolytics.
  • "We are optimistic that pelareorep, in combination with paclitaxel, could significantly enhance clinical outcomes for patients with HR+/HER2- metastatic breast cancer.
  • The company looks forward to meeting with the FDA in Q2 2024 to finalize the trial design and goals for using pelareorep in treating metastatic breast cancer.

Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer

Retrieved on: 
Montag, April 15, 2024
CDK, University, Learning, Risk, Woman, Quantum Leap, Eli Lilly, Recurrence, Atossa, Patient, EOP, MRI, Neoplasm, Eli Lilly and Company, AACR, Therapy, Breast cancer, Pharmaceutical industry

Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.

Key Points: 
  • Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
  • The new study arm will enroll approximately 20 women with newly diagnosed Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) invasive breast cancer.
  • Participants will receive 40mg (Z)-endoxifen once daily in combination with 150mg abemaciclib twice daily for a total of 24 weeks prior to surgery.
  • “Women with high clinical stage but less proliferative tumors (molecularly low risk or those with late recurrence risk) are challenging to treat.

CDK Brings Digital Transformation to Canadian Automotive Retail With New Category of Software: the CDK Dealership Xperience

Retrieved on: 
Dienstag, April 30, 2024
Technology, Automotive, General Automotive, Automotive Manufacturing, Specialty, Telecommunications, Other Automotive, Software, Manufacturing, Retail, Online, CDK, Heart, DMS, Multimedia, Car dealership

CDK Dealership Xperience was initially introduced in the United States in August 2023, and more than 700 CDK dealer partners have signed up for the new platform’s advanced solutions.

Key Points: 
  • CDK Dealership Xperience was initially introduced in the United States in August 2023, and more than 700 CDK dealer partners have signed up for the new platform’s advanced solutions.
  • The Foundations Suite is at the heart of the CDK Dealership Xperience platform and seamlessly integrates with the CDK Modern Retail Suite, the CDK Fixed Operations Suite, and the CDK Intelligence Suite.
  • The CDK Dealership Xperience is available now throughout Canada for new and existing customers.
  • The CDK Dealership Xperience is available now throughout Canada for new and existing customers.